Cannabis
Red Light Holland Reports Second Quarter 2023 Financial Results
- Cash balance of $20.5 million as at September 30, 2022
- Revenue of $736 thousand (2021 – $485 thousand)
- Property and equipment value of $4.7 million
- Total assets of $31.2 million
- Net loss for the quarter was $1.3 million, or ($0.00) per share (2021 – $1.8 million, or ($0.01) per share)
- Acquisition of MiniChamp B.V., a grow at home mushroom kit producer, located in Horst, The Netherlands, with existing sales distribution channels throughout the European Union
Toronto, Ontario–(Newsfile Corp. – November 30, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce that it has filed its financial results for the second fiscal quarter of 2023 ended September 30, 2022, the highlights of which are included in this news release. The condensed interim consolidated financial statements for the three and six months ended September 30, 2022 and the accompanying management’s discussion and analysis (“MD&A“) can be accessed by visiting the Company’s website at www.RedLight.co, and its profile page on SEDAR at www.sedar.com.
“I am pleased to announce that for our second quarter of fiscal 2023 revenue increased 51.6% to $736 thousand and gross profit increased 83.3% to $288 thousand compared to $486 thousand and $157 thousand, respectively, from the same period last year. Our revenue growth represents both the consolidation of recent acquisitions and increased activity levels, specifically the increased production levels at Acadian Exotic Mushrooms Ltd. Our gross profit, which represents 39.1% of sales, has generated strong results through improvements to production efficiencies and prudent spending. As a result, our net loss has improved from $1.8 million in the prior year to $1.3 million in the current year. We are proving that as a Company involved in the psychedelic sector that revenues are happening now! As we move forward, we will continue to focus on top line revenue growth and its conversion to the bottom line,” said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland.
“Operational excellence, customer satisfaction and brand awareness continue to be the pillars of our foundation and drivers of our future growth. The integration of our two new retail stores in Oss and Utrecht in the Netherlands is now complete and we continue to develop our Wellness World brand which is expected to roll out early in calendar 2023. Acadian Exotic Mushroom Ltd., now operating at approximately 80% capacity, continues to increase deliveries of gourmet exotic mushrooms from our production facility in New Brunswick. I am also pleased to report that, subsequent to the quarter end, we closed on our acquisition of MiniChamp B.V., a grow at home mushroom kit producer, located in Horst, The Netherlands, with existing sales distribution channels throughout the European Union. We have learned a ton since acquiring a majority stake of Happy Caps Mushroom Farm back in June of 2021, and we are proud of their growth and remain confident with our decision to focus on the grow-at-home mushroom kit business strategy. As well, while the launch dates have been pushed back a bit, we are very pleased with the progress of the behind-the-scenes creation of MISTERCAP’s home grow mushroom kits, who will be receiving marketing advisory services from Wiz Khalifa as he plans on leveraging his social media presence to promote these legal mushroom products across Canada, United States, and the European Union. We are already focused on lining up supply and production of the MISTERCAP products in anticipation of their launch. I’m tremendously excited to present our brand unveil of MISTERCAP’s in the coming weeks. In my opinion – it’ll be worth the wait,” added Mr. Shapiro.
With regards to the strength of the current financial position, David Ascott, Chief Financial Officer of Red Light Holland, added, “Our financial position and liquidity remains strong, and the Company currently has sufficient capital to fund its ongoing business development and future growth and expansion plans for the foreseeable future. The Company’s working capital as at September 30, 2022 was $20.7 million which included $20.5 million of cash and cash equivalents. For the six months ended September 30, 2022, the Company generated revenues of $1.5 million and gross profit of 577 thousand.”
SUMMARY OF THE THREE MONTHS ENDED SEPTEMBER 30, 2022
- Revenue of $736 thousand (2021 – $486 thousand), generating gross profit of $288 thousand (2021 – $157 thousand), resulting in a gross margin of 39.1% (2021 – 32.3%)
- Net loss for the period was $1.3 million, loss of $0.00 per share (2021 – $1.8 million, loss of $0.01 per share)
- Continued strong financial position, including cash in the amount of $20.5 million;
- On October 4, 2022, the acquired 100% of the issued and outstanding shares of MiniChamp B.V., a grow at home mushroom kit producer, located in Horst, The Netherlands, with existing sales distribution channels throughout the European Union. The acquisition consideration was comprised of €550,000 and 981,466 common shares of Red Light Holland. The Acquisition Agreement also provides for the opportunity for up to €100,000 of earn out payments to be made to the Vendor subject to reaching certain sales milestones
“While in St. Vincent the regulatory progress has remained slow, we are proud and anticipate working further with CCrest Laboratories Inc., in Canada, for further testing, research and product development with our homegrown psilocybin Truffles from our Netherlands farm. As well, in the last quarter we have continued to work with grass root movements and regulatory bodies in the United States and have seen great progress on regulations for legal access to natural Psilocybin and microdosing. Voters in Colorado approved a ballot measure legalizing the use of psilocybin and in Oregon, Measure 109’s current draft rules allow for group services (with regulations) that are mostly aligned to our recommendation, which will hopefully allow for equitable microdosing services. In Washington State, we have been working with the Psilocybin Advisory Board and our lobbyist has been helping promote a legalization bill for next year’s session. On the technology front, we continue to spearhead psychedelic technology, with increased users of our iMicro app, increased deployment of our educational virtual reality in smartshops with the goal of teaching and empowering customers to use natural psilocybin responsibly, while making the most of their experience,” said Sarah Hashkes, Chief Technology and Innovation Officer of Red Light Holland.
“We have also passed all strict regulatory tests for Wisdom (the Moon version) and we’ve had very successful user testing of the Moon MindPlay biofeedback game in large festivals and conferences. Finally, regarding the Wisdom Truffle, as further discussed in our MD&A, we are a bit delayed in production, but our team has done a tremendous job working through Covid and global supply chain issues. Everything is back on track and soon we will be launching a social media campaign, with approximately 30 social media influencers, with our first round of production of the Moon units and shortly after, we will also start pre-sales. Shareholders and future consumers can expect more details and a robust update on the Wisdom Truffle soon. We continue to be very excited to start marketing and ultimately selling Wisdom to the public as soon as possible,” added Sarah Hashkes.
“Our mission remains: to provide affordable and equitable adult access to naturally occurring psilocybin via technology, education, information and responsible use. I am grateful for our shareholders’ continued support and our team’s hard work. As always, feel free to contact me anytime at the email provided below. #FreeTheMagic,” concluded Mr. Shapiro.
Red Light Holland and The MISTERCAP brand are committed to creating educational and responsible use messaging in relation to the use of any products made available by the brand. Red Light Holland and Mistercap LLC will share further details on the MISTERCAP products in both North America and Europe, team, and vision in the weeks to come. MISTERCAP products will be intended to help promote a healthy lifestyle. No MISTERCAP and/or Red Light Holland products are intended to treat or cure any medical conditions and are in no event a substitute for professional medical care. No statements made by Red Light Holland, Mistercap LLC or Wiz Khalifa have been evaluated by the United States Food and Drug Administration or any other similar body of another jurisdiction, and are in no event a substitute for professional medical care. Red Light Holland, Mistercap LLC and Wiz Khalifa encourage all consumers to speak with their doctors and professional medical advisors for any solutions that may be appropriate for each person individually.
ABOUT RED LIGHT HOLLAND
The Company is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Todd Shapiro
Chief Executive Officer and Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones (including, without limitation, the launch, team, vision, supply, production and promotion of MISTERCAP and its products, the launch and production of Wisdom Truffle and Moon units, the development and roll out of the Wellness World brand and the Company’s focus on top line revenue growth and its conversion to the bottom line); the Company’s future growth prospects and intentions to pursue one or more viable business opportunities; the development of the Company’s business, brands and future activities following the date hereof; expectations relating to market size and anticipated growth in the jurisdictions within which the Company may from time to time operate or contemplate future operations; expectations with respect to economic, business, regulatory and/or competitive factors related to the Company or the mushroom and psychedelics industries generally; the market for the Company’s current and proposed product offerings, as well as the Company’s ability to capture market share; the Company’s strategic investments and capital expenditures, and related benefits; the distribution methods expected to be used by the Company to deliver its product offerings; the Company making meaningful increases to its revenue profile; the Company continuing to increase its revenue through the third fiscal quarter of 2023, and the remainder of the year; the Company’s ability to generate cash flow from operations and from financing activities; the Company’s ability to obtain, maintain, and renew or extend, applicable authorizations, including the timing and impact of the receipt thereof; the realization of cost savings, synergies or benefits from the Company’s recent and proposed acquisitions, and the Company’s ability to successfully integrate the operations of any business acquired within the Company’s business; the anticipated sales from continuing operations for the financial year of the Company ending March 31, 2023; the Company hitting its forecasted revenue and sales projections for the remainder of fiscal 2023; the Company providing a robust update on the Wisdom Truffle; and the Company providing affordable and equitable access adult access to naturally occurring psilocybin.
Forward-looking information in this press release are based on certain assumptions and expected future events, namely: current and future members of management will abide by the Company’s business objectives and strategies from time to time established by the Company; the Company will achieve the performance, meet their business objectives and milestones in their anticipated time and within the anticipated cost; the Company will retain and supplement its board of directors and management, or otherwise engage consultants and advisors having knowledge of the industries (or segments thereof) within which the Company may from time to time participate; the Company will have sufficient working capital and the ability to obtain the financing required in order to develop and continue its business, brands and operations; the Company will continue to attract, develop, motivate and retain highly qualified and skilled consultants and/or employees, as the case may be; no adverse changes will be made to the regulatory framework governing psychedelics, mushrooms, taxes and all other applicable matters in the jurisdictions in which the Company conducts business and any other jurisdiction in which the Company may conduct business in the future; the Company will be able to generate cash flow from operations, including, where applicable, distribution and sale of mushrooms and mushroom products; the Company will be able to execute on its business strategy as anticipated; the Company will be able to meet the requirements necessary to obtain and/or maintain authorizations required to conduct the business; general economic, financial, market, regulatory, and political conditions, including the impact of the COVID-19 pandemic, will not negatively affect the Company or its business; the Company will be able to successfully compete in the mushroom and psychedelic industries; mushroom prices will not decline materially; the Company will be able to effectively manage anticipated and unanticipated costs; the Company will be able to conduct its operations in a safe, efficient and effective manner; general market conditions will be favourable with respect to the Company’s future plans and goals; the Company will reach the anticipated sales from continuing operations for the financial year of the Company ending March 31, 2023; the Company will hit its forecasted revenue and sales projections for the remainder of fiscal 2023; the Company will develop its production facilities; the Company will make meaningful increases to its revenue profile; and the Company will provide affordable and equitable access adult access to naturally occurring psilocybin.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to attract and retain qualified members of management to grow the Company’s business, brands and its operations; unanticipated changes in economic and market conditions (including changes resulting from the COVID-19 pandemic) or in applicable laws; the impact of the publications of inaccurate or unfavourable research by securities analysts or other third parties; the Company’s failure to complete future acquisitions or enter into strategic business relationships; interruptions or shortages in the supply of mushrooms available to support the Company’s operations from time to time; unanticipated changes in the mushroom and psychedelic industries in the jurisdictions within which the Company may from time to time conduct its business and operations, including the Company’s inability to respond or adapt to such changes; the Company’s inability to secure or maintain favourable lease arrangements or the required authorizations necessary to conduct the business and operations and meet its targets; the Company’s inability to secure desirable retail store locations on favourable terms; risks relating to projections of the Company’s operations; the Company’s inability to effectively manage unanticipated costs and expenses, including costs and expenses associated with product recalls and judicial or administrative proceedings against the Company; risk that the Company will not reach the anticipated sales from continuing operations for the financial year of the Company ending March 31, 2023; risk that the Company will not hit its forecasted revenue and sales projections for the third fiscal quarter of 2023; risk that same-store sales will not increase, but decease and/or plateau; risk that the Company will be unable to increase its revenue profile; risk that the Company will be unable to increase its revenue through the remainder of fiscal 2023, but that it will decease and/or plateau; risks that the Company will be unable to complete the development of any or all of its production facilities; risk that the Company will be unable to launch, develop, promote, supply, and/or produce their products upon their anticipated timelines; and risk that the Company will be unable to provide affordable and equitable access adult access to naturally occurring psilocybin.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146175
Record Q1 Net Revenue of $177 Million, Representing 15% Growth Year over Year
Increased #1 Cannabis Market Share Position in Canada to 13.4%
Grew Canadian Cannabis Revenue by 16.5% and International Cannabis Revenue by 37%
With Closing of Acquisition of Eight Craft Beer and Beverage Brands, Creating 5th Largest U.S. Craft Beer Brewer with 5% Market Share in Growing Craft Market
Conference Call to be Held at 8:30 a.m. ET Today
NEW YORK and LEAMINGTON, Ontario, Oct. 04, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for its first quarter fiscal year 2024 ended August 31, 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “Today, Tilray Brands is the most diversified global cannabis-lifestyle and CPG company in the world with four distinct and complementary business segments – medical and adult-use cannabis, beverages including, craft beer, spirits, ready to drink mixed cocktails in a can, non-alcoholic drinks, THC and CBD beverages, wellness products, and medical distribution. The balance we have brought to our diversified business model has positioned Tilray Brands as the #1 Canadian cannabis LP, the market leader in medical cannabis across Europe, a leader in the hemp foods industry, and a formidable player in the fast-growing craft beverage-alcohol industry with a growing leadership position. We have strategically diversified our company globally over the past several years and, as a result, Tilray is now ideally positioned to capture a wide range of opportunities across multiple industries driving value through organic and acquisitive revenue growth, operating efficiencies, and improved margins and profitability. We will continue to invest in our future and accelerate our vision of becoming a multi-billion-dollar company with a portfolio of best-in-class brands.”
Mr. Simon continued, “Since the beginning of our FY 2024, we have closed on three transactions: HEXO Corp. in June, Truss Beverage Co. in August, and the acquisition of eight beer and beverage brands from Anheuser-Busch earlier this week. The HEXO and Truss acquisitions have already boosted our competitive cannabis positioning in Canada, the largest, federally legalized cannabis market in the world, by increasing our leading market share, while the beer and beverage brands acquisition has made us the 5th largest craft beer brewer in the U.S., up from the 9th position. We are now working on the seamless integration of these acquisitions into our efficient operating platforms by leveraging our deep CPG expertise and established track record to drive revenue through product innovation and expanded distribution and maximize cost savings through synergy realization.”
Financial Highlights – First Quarter Fiscal Year 2024
- Net revenue increased 15% to $177 million in the first quarter compared to $153 million in the prior year quarter.
- Gross profit was $44 million, while adjusted gross profit was $49 million in the quarter. Gross margin was 25%, while adjusted gross margin declined to 28% from 32% in the prior year quarter.
- Cannabis net revenue increased 20% to $70 million in the first quarter compared to $59 million in the prior year quarter. On a constant currency basis, net cannabis revenue was $71 million in the quarter, up 22% from the prior year quarter.
- Cannabis gross margin decreased to 28% in the quarter from 51% in the prior year quarter and cannabis adjusted gross margin decreased to 35% in the quarter from 51% in the prior year quarter, reflecting the prior year’s inclusion of the HEXO advisory fee revenue and the completion in our first quarter of a wholesale transaction designed to optimize inventory levels and generate $3.1 million of cash.
- Beverage alcohol net revenue increased 17% to $24 million in the first quarter from $21 million in the prior year quarter.
- Beverage alcohol gross margin increased to 53% in the quarter from 47% in the prior year quarter and adjusted gross beverage alcohol margin was 56% in the quarter compared to 53% in the prior quarter, reflecting an increase in beer as a percentage of sales mix along with the positive impact of the Montauk acquisition.
- Distribution net revenue increased 14% to $69 million in the first quarter compared to $61 million in the prior year quarter. On a constant currency basis, distribution revenue was $67 million in the quarter, up 11% from the prior year quarter.
- Distribution gross margin increased to 11% in the quarter from 9% in the prior year quarter, reflecting favorable sales mix and lower production costs.
- Net loss narrowed to $56 million in the first quarter compared to net loss of $66 million in the prior year quarter with a net loss per share of ($0.10) compared to ($0.13).
- Adjusted EBITDA was $11.4 million in the first quarter compared to $13.5 million in the prior year quarter primarily as a result of the prior year including HEXO advisory fee revenue.
- Achieved $17.1 million in annualized run-rate savings (and $2.9 million in actual cash cost savings) as part of the $27 million synergy plan related to the HEXO acquisition. We are on target to achieve our integration plan goals and we are confident HEXO will prove to be a successful acquisition.
- Achieved $6.8 million in annualized run-rate savings in connection with the $8.0 million cost reduction plan in Europe.
- Strong financial liquidity position of ~$466 million, consisting of $179 million in cash, including restricted cash and $287 million in marketable securities.
- Operating cash flow of $(16) million in the first quarter compared to $(46) million in the prior year quarter, representing an improvement of $30 million.
Operating Highlights
Leadership in Global Cannabis Operations, Brands, and Market Share, Further Solidified through Recent HEXO and Truss Acquisitions
- Tilray grew its #1 cannabis market share position to 13.4% in Q1 2024. The Company continues to hold the #1 market position across all major markets and a leading share across most product categories. Tilray is #1 in cannabis Flower, Oils, Concentrates and THC Beverages, and #2 in Pre-Rolls, #4 in Vape, and in the Top 10 in all other categories. The Company closed on the HEXO transaction in June 2023, significantly bolstering its position supported by low-cost operations and complementary distribution across all Canadian geographies.
- By capitalizing on the Company’s unrivaled cultivation and distribution operations and the leadership team’s depth of commercial and regulatory expertise, Tilray is focused on growing its leading market share in medical cannabis in the countries in which it distributes today and achieving early-mover advantage in new countries as cannabis legalization proliferates across Europe and other international markets. During Q1, the increase in international cannabis revenue was largely driven by expansion into emerging international medical markets.
Maximizing the Growth Potential of U.S. CPG and Craft-Beverage Lifestyle Brand Portfolio
- During Q1, Tilray made substantial strides in performance across its five craft-beverage brands including SweetWater Brewing Company, Breckenridge Distillery, and Montauk Brewing Company, growing revenue in its beverage alcohol segment by 17% and adjusted gross profit by 24%. Tilray’s wellness brand, Manitoba Harvest, maintained its brand leadership position in branded hemp with 52% market share and increased its gross margin to 29% from 26% through price increases.
- On September 29, 2023, Tilray closed on its acquisition of eight beer and beverage brands from Anheuser-Busch (NYSE: BUD). The acquired brands, consisting of Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy, possess strong consumer loyalty and further diversify Tilray’s growing U.S. beverage alcohol segment. Their expected sales volume elevate Tilray Brands to the 5th largest position in the high-growth U.S. craft beer market, up from the 9th position.
- Upon federal cannabis legalization in the U.S., Tilray is well-positioned to immediately leverage its strong U.S. leadership position and strategic strengths across distribution and brands to include THC-infused products to maximize all commercial opportunities and drive significant additional revenue in adult-use cannabis through expanded recognition and distribution.
Fiscal Year 2024 Guidance
For its fiscal year ending May 31, 2024, the Company is reiterating its adjusted EBITDA target of $68 million to $78 million representing growth of 11% to 27% as compared to fiscal year 2023. In addition, the Company expects to generate positive adjusted free cash flow.
Management’s guidance for adjusted EBITDA is provided on a non-GAAP basis and excludes transaction expenses, restructuring charges, litigation costs, facility start-up and closure costs, lease expense, purchase price accounting step-up, changes in fair value of contingent consideration and other items carried at fair value, non-operating income (expenses), interest expense, net, income tax expense and other non-recurring items that may be incurred during the Company’s fiscal year 2024, which the Company will continue to identify as it reports its future financial results. Management’s guidance for adjusted free cash flow is provided on a non-GAAP basis and excludes our growth capex, projected integration costs related to HEXO and the cash income taxes related to Aphria Diamond.
The Company cannot reconcile its expected adjusted EBITDA to net income or adjusted free cash flow to operating cash flow under “Fiscal Year 2024 Guidance” without unreasonable effort because of certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time.
Tilray Brands Strategic Growth Actions – Fiscal Year 2024 to date
October 2023
- Tilray Brands Closes Transaction Acquiring Eight Beer & Beverage Brands From Anheuser-Busch; Solidifies Leadership Position in U.S. Craft Beer Market
September 2023
- Potently Canadian’ Cannabis Brand, CANACA, Launches ‘Let ‘Er Rip’ Campaign
- Tilray’s Best-Selling Beers Make Landfall at Atlantis, Bahamas
- Montauk Brewing Expands Distribution Beyond the Northeast
- Tilray Expands Market Leading Cannabis Portfolio with Launch of New Redecan Products Across Canada
August 2023
- RIFF Cannabis Launches New Diamond Infused Pre-Rolls and Blunts
- A New Chilled Ritual is Here: Solei Cannabis Launches Its First Sparkling CBD Beverages
- Tilray Brands Announces Acquisition of Truss Beverage Co.™
- Good Supply’s Fan Favourite Cannabis Strains Just Got ‘Juiced’
- Breckenridge Distillery Announces New and Expanded Partnership with the Denver Broncos
- Tilray Brands Announces Agreement to Acquire Eight Beer & Beverage Brands From Anheuser-Busch, Fueling Tilray’s Future in the U.S. Craft Beer Industry
- Montauk Brewing Further Expands Distribution Across Northeast and Launches Market Presence in Pennsylvania
July 2023
- Tilray Renews Distribution Agreement With Great North Distributors for Cannabis Sales Across Canada With Newly Expanded Brand Portfolio
- SweetWater Brewing Announces Partnership with ATLive and Mercedes Benz Stadium
- RIFF Cannabis Brand Launches New THC Beverages for Summer
- SweetWater Brewing Launches Gummies Beer A New Juicy Revolution
June 2023
- Tilray Brands Completes Acquisition of HEXO Corp. Leading Next Evolution of Canadian Cannabis
- Breckenridge Distillery Launches New Limited Release Collectors Art Series
- Montauk Brewing Company Celebrates 11-Year Anniversary and 2023 Summer Season Lineup
- Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Live Conference Call and Audio Webcast
Tilray Brands will host a webcast to discuss these results today at 8:30 a.m. ET. Investors may join the live webcast available on the Investors section of the Company’s website at www.tilray.com. A replay will be available and archived on the Company’s website.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with four distinct and complementary business segments including medical and adult-use cannabis, medical distribution, wellness foods, and beverage-alcohol. Tilray Brands is on a mission to change people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis and consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, today Tilray Brands’ unprecedented and diversified production platform supports a portfolio of best-in-class brands in over 20 countries including comprehensive adult-use and medical cannabis offerings, hemp-based foods, and craft beverages across North America, Europe, Australia, and Latin America.
For more information on Tilray Brands, visit www.Tilray.com and follow @Tilray
Cautionary Statement Concerning Forward-Looking Statements
Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world’s leading cannabis-focused consumer branded company; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve revenue growth, production and supply chain efficiencies, synergies and cost savings; the Company’s ability to generate $68-$78 million of Adjusted EBITDA and expectation to be cash-flow positive in its operating business in fiscal year 2024; the Company’s expected revenue growth, sales volume, profitability, synergies and accretion related to any of its acquisitions; expected opportunities upon U.S. federal legalization; the Company’s anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives; and the Company’s ability to commercialize new and innovative products.
Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including Adjusted gross margin, Adjusted gross profit, Adjusted EBITDA, free cash flow, adjusted free cash flow, constant currency presentations of revenue and cash and marketable securities. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company’s operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company’s Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.
Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company’s GAAP financial results.
The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company’s consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.
Adjusted EBITDA is calculated as net income (loss) before income tax benefits, net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; facility start-up and closure costs; lease expense; litigation costs; restructuring costs and transaction (income) costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted gross profit, is calculated as gross profit adjusted to exclude the impact of inventory valuation adjustment and purchase price accounting valuation step-up. A reconciliation of Adjusted gross profit, excluding purchase price accounting valuation step-up, to gross profit, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted gross margin, excluding inventory valuation adjustments and purchase price accounting valuation step-up, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Adjusted gross margin, excluding inventory valuation adjustments and purchase price accounting valuation step-up, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net, and the exclusion of growth CAPEX from investments in capital and intangible assets, net, which excludes the amount of capital expenditures that are considered to be associated with growth of future operations rather than to maintain the existing operations of the Company, and excludes our projected integration costs related to HEXO and the cash income taxes related to Aphria Diamond to align with management’s prescribed guidance. A reconciliation of net cash flow provided by (used in) operating activities to adjusted free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Constant currency presentations of revenue are used to normalize the effects of foreign currency. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. Dollar are translated into U.S. Dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. A reconciliation of prior year revenue to constant currency revenue the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Cash and marketable securities are comprised of two GAAP measures, cash and cash equivalents added to marketable securities. The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combing these two GAAP metrics.
For further information:
Media: Berrin Noorata, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com
| Consolidated Statements of Financial Position | |||||||
| August 31, | May 31, | ||||||
| (in thousands of US dollars) | 2023 | 2023 | |||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 177,519 | $ | 206,632 | |||
| Restricted cash | 1,613 | – | |||||
| Marketable securities | 287,333 | 241,897 | |||||
| Accounts receivable, net | 82,076 | 86,227 | |||||
| Inventory | 232,075 | 200,551 | |||||
| Prepaids and other current assets | 44,943 | 37,722 | |||||
| Assets held for sale | 3,696 | – | |||||
| Total current assets | 829,255 | 773,029 | |||||
| Capital assets | 494,619 | 429,667 | |||||
| Right-of-use assets | 5,605 | 5,941 | |||||
| Intangible assets | 967,568 | 973,785 | |||||
| Goodwill | 2,009,673 | 2,008,843 | |||||
| Interest in equity investees | 4,638 | 4,576 | |||||
| Long-term investments | 7,564 | 7,795 | |||||
| Convertible notes receivable | 74,681 | 103,401 | |||||
| Other assets | 8,647 | 222 | |||||
| Total assets | $ | 4,402,250 | $ | 4,307,259 | |||
| Liabilities | |||||||
| Current liabilities | |||||||
| Bank indebtedness | $ | 14,594 | $ | 23,381 | |||
| Accounts payable and accrued liabilities | 238,081 | 190,682 | |||||
| Contingent consideration | 7,181 | 16,218 | |||||
| Warrant liability | 10,015 | 1,817 | |||||
| Current portion of lease liabilities | 2,324 | 2,423 | |||||
| Current portion of long-term debt | 13,489 | 24,080 | |||||
| Current portion of convertible debentures payable | 251,590 | 174,378 | |||||
| Total current liabilities | 537,274 | 432,979 | |||||
| Long – term liabilities | |||||||
| Contingent consideration | 13,000 | 10,889 | |||||
| Lease liabilities | 7,462 | 7,936 | |||||
| Long-term debt | 152,390 | 136,889 | |||||
| Convertible debentures payable | 120,861 | 221,044 | |||||
| Deferred tax liabilities | 169,633 | 167,364 | |||||
| Other liabilities | 74 | 215 | |||||
| Total liabilities | 1,000,694 | 977,316 | |||||
| Commitments and contingencies (refer to Note 18) | |||||||
| Stockholders’ equity | |||||||
| Common stock ($0.0001 par value; 980,000,000 common shares; 723,292,600 and 656,655,455 common shares issued and outstanding, respectively) | 72 | 66 | |||||
| Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively) | – | – | |||||
| Additional paid-in capital | 5,909,895 | 5,777,743 | |||||
| Accumulated other comprehensive loss | (43,561 | ) | (46,610 | ) | |||
| Accumulated Deficit | (2,487,032 | ) | (2,415,507 | ) | |||
| Total Tilray Brands, Inc. stockholders’ equity | 3,379,374 | 3,315,692 | |||||
| Non-controlling interests | 22,182 | 14,251 | |||||
| Total stockholders’ equity | 3,401,556 | 3,329,943 | |||||
| Total liabilities and stockholders’ equity | $ | 4,402,250 | $ | 4,307,259 | |||
| Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) | ||||||||||||||
| For the three months | ||||||||||||||
| ended August 31, | Change | % Change | ||||||||||||
| (in thousands of U.S. dollars, except for per share data) | 2023 | 2022 | 2023 vs. 2022 | |||||||||||
| Net revenue | $ | 176,949 | $ | 153,211 | $ | 23,738 | 15 | % | ||||||
| Cost of goods sold | 132,753 | 104,597 | 28,156 | 27 | % | |||||||||
| Gross profit | 44,196 | 48,614 | (4,418 | ) | (9 | )% | ||||||||
| Operating expenses: | ||||||||||||||
| General and administrative | 40,516 | 40,508 | 8 | 0 | % | |||||||||
| Selling | 6,859 | 9,671 | (2,812 | ) | (29 | )% | ||||||||
| Amortization | 22,225 | 24,359 | (2,134 | ) | (9 | )% | ||||||||
| Marketing and promotion | 8,535 | 7,248 | 1,287 | 18 | % | |||||||||
| Research and development | 79 | 166 | (87 | ) | (52 | )% | ||||||||
| Change in fair value of contingent consideration | (11,107 | ) | 211 | (11,318 | ) | (5,364 | )% | |||||||
| Litigation costs | 2,034 | 445 | 1,589 | 357 | % | |||||||||
| Restructuring costs | 915 | — | 915 | 0 | % | |||||||||
| Transaction (income) costs | 8,502 | (12,816 | ) | 21,318 | (166 | )% | ||||||||
| Total operating expenses | 78,558 | 69,792 | 8,766 | 13 | % | |||||||||
| Operating loss | (34,362 | ) | (21,178 | ) | (13,184 | ) | 62 | % | ||||||
| Interest expense, net | (9,835 | ) | (4,413 | ) | (5,422 | ) | 123 | % | ||||||
| Non-operating income (expense), net | (4,402 | ) | (32,992 | ) | 28,590 | (87 | )% | |||||||
| Loss before income taxes | (48,599 | ) | (58,583 | ) | 9,984 | (17 | )% | |||||||
| Income tax expense | 7,264 | 7,211 | 53 | 1 | % | |||||||||
| Net loss | $ | (55,863 | ) | $ | (65,794 | ) | $ | 9,931 | (15 | )% | ||||
| Net loss per share – basic and diluted | $ | (0.10 | ) | $ | (0.13 | ) | $ | 0.02 | (19 | )% | ||||
| Condensed Consolidated Statements of Cash Flows | |||||||||||||
| For the three months | |||||||||||||
| ended August 31, | Change | % Change | |||||||||||
| (in thousands of US dollars) | 2023 | 2022 | 2023 vs. 2022 | ||||||||||
| Cash used in operating activities: | |||||||||||||
| Net loss | $ | (55,863 | ) | $ | (65,794 | ) | $ | 9,931 | (15)% | ||||
| Adjustments for: | |||||||||||||
| Deferred income tax recovery | 59 | 796 | (737 | ) | (93)% | ||||||||
| Unrealized foreign exchange (gain) loss | (3,127 | ) | 10,026 | (13,153 | ) | (131)% | |||||||
| Amortization | 30,789 | 34,069 | (3,280 | ) | (10)% | ||||||||
| Loss on sale of capital assets | 3 | 77 | (74 | ) | (96)% | ||||||||
| Other non-cash items | (816 | ) | 2,080 | (2,896 | ) | (139)% | |||||||
| Stock-based compensation | 8,257 | 9,193 | (936 | ) | (10)% | ||||||||
| Loss on long-term investments & equity investments | 47 | 1,193 | (1,146 | ) | (96)% | ||||||||
| Loss on derivative instruments | 10,345 | 6,336 | 4,009 | 63% | |||||||||
| Change in fair value of contingent consideration | (11,107 | ) | 211 | (11,318 | ) | (5,364)% | |||||||
| Change in non-cash working capital: | |||||||||||||
| Accounts receivable | 13,044 | (3,068 | ) | 16,112 | (525)% | ||||||||
| Prepaids and other current assets | (4,654 | ) | (34,891 | ) | 30,237 | (87)% | |||||||
| Inventory | 3,650 | (232 | ) | 3,882 | (1,673)% | ||||||||
| Accounts payable and accrued liabilities | (6,469 | ) | (6,265 | ) | (204 | ) | 3% | ||||||
| Net cash used in operating activities | (15,842 | ) | (46,269 | ) | 30,427 | (66)% | |||||||
| Cash used in investing activities: | |||||||||||||
| Investment in capital and intangible assets, net | (4,152 | ) | (3,000 | ) | (1,152 | ) | 38% | ||||||
| Proceeds from disposal of capital and intangible assets | 342 | 1,463 | (1,121 | ) | (77)% | ||||||||
| Purchase of marketable securities, net | (45,436 | ) | – | (45,436 | ) | 0% | |||||||
| Net cash acquired from business acquisitions | 22,956 | – | 22,956 | 0% | |||||||||
| Net cash used in investing activities | (26,290 | ) | (1,537 | ) | (24,753 | ) | 1,610% | ||||||
| Cash provided by (used in) financing activities: | |||||||||||||
| Share capital issued, net of cash issuance costs | – | 129,593 | (129,593 | ) | (100)% | ||||||||
| Shares effectively repurchased for employee withholding tax | – | (1,189 | ) | 1,189 | (100)% | ||||||||
| Proceeds from long-term debt and convertible debt | 29,174 | 1,288 | 27,886 | 2,165% | |||||||||
| Repayment of long-term debt and convertible debt | (6,369 | ) | (5,196 | ) | (1,173 | ) | 23% | ||||||
| Repayment of lease liabilities | – | (1,035 | ) | 1,035 | (100)% | ||||||||
| Net increase in bank indebtedness | (8,787 | ) | 159 | (8,946 | ) | (5,626)% | |||||||
| Net cash provided by (used in) financing activities | 14,018 | 123,620 | (109,602 | ) | (89)% | ||||||||
| Effect of foreign exchange on cash and cash equivalents | 614 | (1,080 | ) | 1,694 | (157)% | ||||||||
| Net decrease in cash and cash equivalents | (27,500 | ) | 74,734 | (102,234 | ) | (137)% | |||||||
| Cash and cash equivalents, beginning of period | 206,632 | 415,909 | (209,277 | ) | (50)% | ||||||||
| Cash and cash equivalents, end of period | $ | 179,132 | $ | 490,643 | $ | (311,511 | ) | (63)% | |||||
| Net Revenue by Operating Segment | |||||||||||
| For the three months | For the three months | ||||||||||
| (In thousands of U.S. dollars) | August 31, 2023 | % of Total Revenue | August 31, 2022 | % of Total Revenue | |||||||
| Cannabis business | $ | 70,333 | 39% | $ | 58,570 | 38% | |||||
| Distribution business | 69,157 | 39% | 60,585 | 40% | |||||||
| Beverage alcohol business | 24,162 | 14% | 20,654 | 13% | |||||||
| Wellness business | 13,297 | 8% | 13,402 | 9% | |||||||
| Total net revenue | $ | 176,949 | 100% | $ | 153,211 | 100% | |||||
| Net Revenue by Operating Segment in Constant Currency | |||||||||||
| For the three months | For the three months | ||||||||||
| August 31, 2023 | August 31, 2022 | ||||||||||
| (In thousands of U.S. dollars) | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | |||||||
| Cannabis business | $ | 71,389 | 40% | $ | 58,570 | 38% | |||||
| Distribution business | 66,952 | 38% | 60,585 | 40% | |||||||
| Beverage alcohol business | 24,162 | 14% | 20,654 | 13% | |||||||
| Wellness business | 13,459 | 8% | 13,402 | 9% | |||||||
| Total net revenue | $ | 175,962 | 100% | $ | 153,211 | 100% | |||||
| Net Cannabis Revenue by Market Channel | |||||||||||
| For the three months | For the three months | ||||||||||
| (In thousands of U.S. dollars) | August 31, 2023 | % of Total Revenue | August 31, 2022 | % of Total Revenue | |||||||
| Revenue from Canadian medical cannabis | $ | 6,142 | 9% | $ | 6,520 | 11% | |||||
| Revenue from Canadian adult-use cannabis | 71,195 | 102% | 58,355 | 100% | |||||||
| Revenue from wholesale cannabis | 5,295 | 7% | 392 | 1% | |||||||
| Revenue from international cannabis | 14,252 | 20% | 10,422 | 18% | |||||||
| Less excise taxes | (26,551 | ) | -38% | (17,119 | ) | -30% | |||||
| Total | $ | 70,333 | 100% | $ | 58,570 | 100% | |||||
| Net Cannabis Revenue by Market Channel in Constant Currency | |||||||||||
| For the three months | For the three months | ||||||||||
| August 31, 2023 | August 31, 2022 | ||||||||||
| (In thousands of U.S. dollars) | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | |||||||
| Revenue from Canadian medical cannabis | $ | 6,310 | 9% | $ | 6,520 | 11% | |||||
| Revenue from Canadian adult-use cannabis | 73,111 | 102% | 58,355 | 100% | |||||||
| Revenue from wholesale cannabis | 5,458 | 8% | 392 | 1% | |||||||
| Revenue from international cannabis | 13,777 | 19% | 10,422 | 18% | |||||||
| Less excise taxes | (27,267 | ) | -38% | (17,119 | ) | -30% | |||||
| Total | $ | 71,389 | 100% | $ | 58,570 | 100% | |||||
| Other Financial Information: Key Operating Metrics | |||||
| For the three months | |||||
| ended August 31, | |||||
| (in thousands of U.S. dollars) | 2023 | 2022 | |||
| Net cannabis revenue | $ | 70,333 | $ | 58,570 | |
| Distribution revenue | 69,157 | 60,585 | |||
| Net beverage alcohol revenue | 24,162 | 20,654 | |||
| Wellness revenue | 13,297 | 13,402 | |||
| Cannabis costs | 50,517 | 28,861 | |||
| Beverage alcohol costs | 11,266 | 10,849 | |||
| Distribution costs | 61,468 | 54,984 | |||
| Wellness costs | 9,502 | 9,903 | |||
| Adjusted gross profit (excluding PPA step-up)(1) | 49,302 | 49,721 | |||
| Cannabis adjusted gross margin (excluding PPA step-up)(1) | 35% | 51% | |||
| Beverage alcohol adjusted gross margin (excluding PPA step-up)(1) | 56% | 53% | |||
| Distribution gross margin | 11% | 9% | |||
| Wellness gross margin | 29% | 26% | |||
| Adjusted EBITDA(1) | 11,434 | 13,531 | |||
| Cash and marketable securities(1)as at the period ended: | 464,852 | 490,643 | |||
| Working capital as at the period ended: | 291,981 | 637,623 | |||
| Other Financial Information: Gross Margin and Adjusted Gross Margin | ||||||||||||||
| For the three months ended August 31, 2023 | ||||||||||||||
| (In thousands of U.S. dollars) | Cannabis | Beverage | Distribution | Wellness | Total | |||||||||
| Net revenue | $ | 70,333 | $ | 24,162 | $ | 69,157 | $ | 13,297 | $ | 176,949 | ||||
| Cost of goods sold | 50,517 | 11,266 | 61,468 | 9,502 | 132,753 | |||||||||
| Gross profit | 19,816 | 12,896 | 7,689 | 3,795 | 44,196 | |||||||||
| Gross margin | 28% | 53% | 11% | 29% | 25% | |||||||||
| Adjustments: | ||||||||||||||
| Purchase price accounting step-up | 4,516 | 590 | – | – | 5,106 | |||||||||
| Adjusted gross profit | 24,332 | 13,486 | 7,689 | 3,795 | 49,302 | |||||||||
| Adjusted gross margin | 35% | 56% | 11% | 29% | 28% | |||||||||
| For the three months ended August 31, 2022 | ||||||||||||||
| (In thousands of U.S. dollars) | Cannabis | Beverage | Distribution | Wellness | Total | |||||||||
| Net revenue | $ | 58,570 | $ | 20,654 | $ | 60,585 | $ | 13,402 | $ | 153,211 | ||||
| Cost of goods sold | 28,861 | 10,849 | 54,984 | 9,903 | 104,597 | |||||||||
| Gross profit | 29,709 | 9,805 | 5,601 | 3,499 | 48,614 | |||||||||
| Gross margin | 51% | 47% | 9% | 26% | 32% | |||||||||
| Adjustments: | ||||||||||||||
| Purchase price accounting step-up | – | 1,107 | – | – | 1,107 | |||||||||
| Adjusted gross profit | 29,709 | 10,912 | 5,601 | 3,499 | 49,721 | |||||||||
| Adjusted gross margin | 51% | 53% | 9% | 26% | 32% | |||||||||
| Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization | |||||||||||||
| For the three months | |||||||||||||
| ended August 31, | Change | % Change | |||||||||||
| (In thousands of U.S. dollars) | 2023 | 2022 | 2023 vs. 2022 | ||||||||||
| Net loss | $ | (55,863 | ) | $ | (65,794 | ) | $ | 9,931 | (15)% | ||||
| Income tax expense | 7,264 | 7,211 | 53 | 1% | |||||||||
| Interest expense, net | 9,835 | 4,413 | 5,422 | 123% | |||||||||
| Non-operating income (expense), net | 4,402 | 32,992 | (28,590 | ) | (87)% | ||||||||
| Amortization | 30,789 | 34,069 | (3,280 | ) | (10)% | ||||||||
| Stock-based compensation | 8,257 | 9,193 | (936 | ) | (10)% | ||||||||
| Change in fair value of contingent consideration | (11,107 | ) | 211 | (11,318 | ) | (5,364)% | |||||||
| Purchase price accounting step-up | 5,106 | 1,107 | 3,999 | 361% | |||||||||
| Facility start-up and closure costs | 600 | 1,800 | (1,200 | ) | (67)% | ||||||||
| Lease expense | 700 | 700 | – | 0% | |||||||||
| Litigation costs | 2,034 | 445 | 1,589 | 357% | |||||||||
| Restructuring costs | 915 | – | 915 | NM | |||||||||
| Transaction (income) costs | 8,502 | (12,816 | ) | 21,318 | (166)% | ||||||||
| Adjusted EBITDA | $ | 11,434 | $ | 13,531 | $ | (2,097 | ) | (15)% | |||||
| Other Financial Information: Free Cash Flow and Adjusted Free Cash Flow | |||||||||||||
| For the three months | |||||||||||||
| ended August 31, | Change | % Change | |||||||||||
| (In thousands of U.S. dollars) | 2023 | 2022 | 2023 vs. 2022 | ||||||||||
| Net cash used in operating activities | $ | (15,842 | ) | $ | (46,269 | ) | $ | 30,427 | (66)% | ||||
| Less: investments in capital and intangible assets, net | (3,810 | ) | (1,537 | ) | (2,273 | ) | 148% | ||||||
| Free cash flow | $ | (19,652 | ) | $ | (47,806 | ) | $ | 28,154 | (59)% | ||||
| Add: growth CAPEX | 1,687 | – | 1,687 | NM | |||||||||
| Add: cash income taxes related to Aphria Diamond | 5,714 | 5,487 | 227 | 4% | |||||||||
| Add: integration costs related to HEXO | 5,915 | – | 5,915 | NM | |||||||||
| Adjusted free cash flow | $ | (6,336 | ) | $ | (42,319 | ) | $ | 35,983 | (85)% | ||||
The receipt of the patent confirms the innovation and uniqueness of the Company’s technologies and strengthens its position as a leader in the cannabis space
TEL AVIV, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that The European Patent Office has granted it a new patent – European Application No. 16786064.2, title: Combinations of Cannabinoids and N-Acylethanolamines (the “Patent”). This Patent aligns with the Company’s objective to increase the safety of cannabinoids treatments while maintaining their therapeutic effects.
With this grant, the Company has been granted this patent in the United States, Japan and Australia, supporting the innovation of SciSparc in its technologies.
The Patent relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of selected cannabinoids of the cannabis plant. The Patent provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines and methods for their use in a variety of indications amenable to treatment with cannabinoids.
“SciSparc’s assets continue to expand, both intellectual property alongside revenue generating assets,” said SciSparc’s Chief Executive Officer, Oz Adler. “The Company continues to be a leader in this space with a robust IP portfolio worldwide. We continue to believe that cannabinoid-based medicines have enormous therapeutic potential and therefore we continue to strengthen the patent protection around the technologies we develop”.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses that the therapeutic potential of cannabinoid-based medicines. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
Cannabis
Global Cannabidiol (CBD) Market Report 2023-2027 & 2032 Featuring Major Players – ENDOCA, Cannoid, Medical Marijuana, Inc, Folium Biosciences, & Elixinol
Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) — The “Cannabidiol Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.
The global cannabidiol market grew from $6.82 billion in 2022 to $9.4 billion in 2023 at a compound annual growth rate (CAGR) of 37.8%. The cannabidiol market is expected to grow to $31.85 billion in 2027 at a CAGR of 35.7%.
The cannabidiol (CBD) market encompasses a range of CBD products, including full-spectrum CBD, broad-spectrum CBD, and CBD isolate, with values reflecting the factory gate values or the prices at which manufacturers and creators sell their goods. These goods are distributed to downstream manufacturers, wholesalers, distributors, retailers, and end customers, and the market’s value includes related services offered by the creators of these CBD products.
CBD, derived from cannabis plants, serves various purposes, from treating epilepsy, anxiety, and pain to addressing conditions like dystonia, Parkinson’s disease, and Crohn’s disease. It also finds applications in coffee and skincare products and pet treats.
In 2022, North America emerged as the largest region in the cannabidiol market, while the Asia-Pacific region is projected to witness the fastest growth in the forecast period. The market report covers regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Cannabidiol products come in various forms, including oils, tinctures, suppositories, transdermal patches, vape oils, isolates, creams, roll-ons, capsules, tablets, and more. CBD oil, for instance, is extracted from cannabis plants and diluted with carrier oils like coconut or hemp seed oil. These products have diverse applications, from medical and personal use to pharmaceuticals and wellness, and they are distributed through channels such as hospital pharmacies, retail pharmacies, online stores, and others.
One driving force behind the cannabidiol market’s growth is the increasing acceptance and use of CBD products, thanks to government approvals. Recognizing the potential medical benefits of cannabidiol, governments worldwide are taking steps to improve regulatory pathways for lawful CBD product marketing, ensuring public health while promoting market growth. For instance, in January 2022, Australia’s Therapeutic Goods Administration approved a substantial number of SAS Category B applications for unapproved medicinal cannabis products.
Product innovation is a noteworthy trend in the cannabidiol market, allowing companies to stand out in a competitive landscape and attract more customers. For example, Cibdol, a Netherlands-based CBD and wellness company, launched its exclusive CBD Oil 2.0 range in December 2021, featuring higher levels of essential compounds like CBC, CBG, CBN, and CBDa alongside pure CBD. This innovative CBD oil formula addresses various modern living-related challenges, from appetite and mood to pain and sleep.
Additionally, in August 2021, Canada-based greenhouse produce company Village Farms International Inc. acquired Balanced Health Botanicals for $75 million, strengthening its position in the US retail CBD market. Balanced Health Botanicals is known for producing high-quality health and wellness products in the hemp-derived CBD market, aligning with Village Farms International Inc.’s expansion goals.
These developments underscore the dynamic nature of the cannabidiol market, driven by factors like government approvals and product innovation, promising growth and evolution in the foreseeable future.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 – 2027 |
| Estimated Market Value (USD) in 2023 | $9.4 billion |
| Forecasted Market Value (USD) by 2027 | $31.85 billion |
| Compound Annual Growth Rate | 35.7% |
| Regions Covered | Global |
Major players in the cannabidiol market are
- ENDOCA
- Cannoid, LLC
- Medical Marijuana, Inc.
- Folium Biosciences
- Elixinol
- NuLeaf Naturals, LLC
- Isodiol International, Inc.
- Pharmahemp d.o.o.
- Canopy Growth Corp
- CV Sciences Inc.
- Endoca BV
- Medterra
- The Cronos Group
- CBD American Shaman LLC
- Walgreens Boots Alliance
- Aphria, Inc.
- Maricann, Inc.
- Tilray
- Organigram Holding, Inc.
- CannTrust
Key Topics Covered:
1. Executive Summary
2. Cannabidiol Market Characteristics
3. Cannabidiol Market Trends And Strategies
4. Cannabidiol Market – Macro Economic Scenario
4.1 COVID-19 Impact On Cannabidiol Market
4.2 Ukraine-Russia War Impact On Cannabidiol Market
4.3 Impact Of High Inflation On Cannabidiol Market
5. Cannabidiol Market Size And Growth
5.1. Global Cannabidiol Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Cannabidiol Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Cannabidiol Market Segmentation
6.1. Global Cannabidiol Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
- Oil
- Tinctures
- Suppository
- Transdermal Patches
- Vape Oil
- Isolates
- Creams And Roll-On
- Capsules
- Tablet
- Other Products
6.2. Global Cannabidiol Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
- Marijuana
- Hemp
6.3. Global Cannabidiol Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
- CBD Oil
- Supplements
6.4. Global Cannabidiol Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
- Medical
- Personal Use
- Pharmaceuticals
- Wellness
6.5. Global Cannabidiol Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
- Other Distribution Channels
7. Cannabidiol Market Regional And Country Analysis
7.1. Global Cannabidiol Market, Split By Region, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
7.2. Global Cannabidiol Market, Split By Country, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/j8zzen
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
-
Cannabis2 weeks agoLegal Cannabis Commercialization Bolsters Vacuum Oven Demand; Essential Role in Processing Extracts and Enhancing Safety Recognized
-
Cannabis2 weeks agoNew to The Street Announces its Five Corporate Interviews, airings on Newsmax and FOX Business Network
-
Cannabis2 weeks agoCBD Skin Care Market Size is projected to reach USD 6466.43 million by 2030, growing at a CAGR of 32.15%: Straits Research
-
Cannabis1 week agoGlobal Exosomes Market Size to Reach USD 3.08 Billion in 2032 | Emergen Research
-
Latest News1 week agoCanopy Growth Announces Results of Annual General and Special Meeting of Shareholders
-
Cannabis6 days agoHemp, Inc. Reports: Growing Legalization of Industrial Hemp Driving Global Demand for Hemp
-
Cannabis1 week agoGlobal CBD Oil Market to Reach US$ 5.98 billion by 2033, growing at a CAGR of 31% | Future Market Insights, Inc.
-
Cannabis6 days agoAstrotech Reports Fiscal Year 2023 Financial Results